US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (DAWN) ニュース

DAWN

Day One Biopharmaceuticals (DAWN)

Day One Biopharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:DAWN

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/30	21 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/29	07 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/25	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/18	07 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/18	07 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/17	07 : 34	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/17	07 : 21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/15	07 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/07	05 : 35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/05/07	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/03/08	06 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/02/29	09 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/02/28	06 : 27	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/02/21	08 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/02/21	08 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/02/17	07 : 51	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/01/17	22 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/01/10	09 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/01/10	09 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/01/08	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2024/01/05	06 : 06	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/18	08 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/18	08 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/17	21 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/17	08 : 24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/16	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/07	06 : 48	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/11/07	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/10/30	23 : 54	Dow Jones News	Day One Biopharmaceuticals Shares Rally on FDA Priority Review	NASDAQ:DAWN	Day One Biopharmaceuticals Inc
2023/10/30	21 : 58	Dow Jones News	Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor	NASDAQ:DAWN	Day One Biopharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:DAWN

1 2 3 4 5 6 次へ >>

American Express

Financial Select Sector

BNP Paribas (QX)

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Health Care Select Sector

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約